VGX™-1027 anti-inflammatory drug
VGX™-1027 is an orally administered, small molecule drug for inflammatory diseases. A novel inhibitor of pro-inflammatory responses including TNF-alpha, this drug has demonstrated preclinical efficacy against Crohn’s disease and colitis, rheumatoid arthritis (RA), and Type 1 diabetes (T1D).
VGX-1027 has completed a phase I single-ascending dose, double-blind study in healthy volunteers in which the compound was generally well-tolerated. In keeping with its focus on its synthetic vaccine technology, Inovio plans to out-license this compound.
Inflammatory bowel disease is a broad term that describes conditions with chronic or recurring immune response and inflammation of the gastrointestinal tract. The two most common inflammatory bowel diseases are ulcerative colitis and Crohn’s disease. The Centers for Disease Control estimates that as many as 1.4 million persons in the United States suffer from these diseases.
There is no known pharmaceutical or surgical cure for inflammatory bowel diseases. Current treatment includes corticosteroids, antibiotics and new biologics and immune modifiers that mitigate symptoms but do not prevent or cure the disease.
In the U.S. alone, 1.3 million people suffer from RA according to the National Institute of Arthritis and Musculoskeletal Skin Diseases. With significant unmet clinical need and the progressive introduction of higher value and more effective biopharmaceuticals, the rheumatoid arthritis market is expected to more than double in value to $27 billion by 2015. Type 1 diabetes (T1D), which can be fatal if untreated, usually strikes children and young adults, although it can strike at any age. In adults, T1D accounts for 5 to 10 percent (0.9 million -1.8 million people) of all diagnosed cases of diabetes in the U.S. alone. Risk factors for T1D may be autoimmune, genetic, or environmental. No known way to prevent type 1 diabetes exists.
By following the link to Inovio's website you can find four abstracts dating from 2007-2008. Information since has been very been limited. Inovio's CEO has been quite over the last few years in regards to clinical work concerning VGX-1027, failing to mentioning the clinical work in any of the company's investor conference presentations. I will note Inovio has a broad pipeline preclinical and clinical and not all data is released via PR update, many studies can be found on pubmed or in medical journals online.
Below I have listed so the most recent updates for VGX-1027
1) March 26th, 2009-VGX Pharmaceuticals Oral Inflammatory Drug Safe In Phase 1 Study
2) July 13th, 2012- Therapeutic Potential of Nitric Oxide -Modified Drugs In Colon Cancer Cells
3) October 24th, 2013 Compounds Having Immunomodulator Activity- Patent (WO2013158794A1)
4) February 14th, 2014 Newest Publication for VGX 1027